146 related articles for article (PubMed ID: 4371345)
1. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.
Malarkey WB; Cyrus J; Paulson GW
J Clin Endocrinol Metab; 1974 Aug; 39(2):229-35. PubMed ID: 4371345
[No Abstract] [Full Text] [Related]
2. Stimulation of human-growth-hormone secretion by L-dopa.
Boyd AE; Lebovitz HE; Pfeiffer JB
N Engl J Med; 1970 Dec; 283(26):1425-9. PubMed ID: 5481776
[No Abstract] [Full Text] [Related]
3. [Effect of L-dopa on pituitary TSH and GH secretion in Parkinson's disease].
Sakoda M; Kusaka T; Baba S; Shirakata S
Nihon Naibunpi Gakkai Zasshi; 1972 Jul; 48(4):241-4. PubMed ID: 5066290
[No Abstract] [Full Text] [Related]
4. Amantadine enhancement of L-DOPA induced growth hormone stimulation.
Massara F; Camanni F; Molinatti GM
Horm Metab Res; 1973 Nov; 5(6):454-6. PubMed ID: 4767002
[No Abstract] [Full Text] [Related]
5. The effect of L-dopa on plasma growth hormone, insulin, and thyroxine.
Kansal PC; Buse J; Talbert OR; Buse MG
J Clin Endocrinol Metab; 1972 Jan; 34(1):99-105. PubMed ID: 5061778
[No Abstract] [Full Text] [Related]
6. Blood levels of FSH, LH, TSH, and GH in parkinsonian patients before and during L-dopa treatment.
Lundberg PO
Acta Neurol Scand; 1972; 48(4):427-32. PubMed ID: 5072652
[No Abstract] [Full Text] [Related]
7. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
Cavagnini F; Peracchi M; Scotti G; Raggi U; Pontiroli AE; Bana R
J Endocrinol; 1972 Sep; 54(3):425-33. PubMed ID: 5071365
[No Abstract] [Full Text] [Related]
8. Release of human growth hormone, follicle stimulating hormone, and luteinizing hormone in response to L-dihydroxy-phenylalanine (L-dopa) in normal man.
Perlow MJ; Sassin JF; Boyar R; Hellman L; Weitzman ED
Dis Nerv Syst; 1972 Dec; 33(12):804-10. PubMed ID: 4668972
[No Abstract] [Full Text] [Related]
9. [Silent period in patients with Parkinson's disease treated with L-Dopa].
Palao Sánchez A
Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780
[No Abstract] [Full Text] [Related]
10. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.
Sirtori CR; Bolme P; Azarnoff DL
N Engl J Med; 1972 Oct; 287(15):729-33. PubMed ID: 5056733
[No Abstract] [Full Text] [Related]
11. The influence of levodopa and adrenergic blockade on growth hormone and prolactin secretion in the MStTW15 tumor bearing rat.
Malarkey WB; Daughaday WH
Endocrinology; 1972 Nov; 91(5):1314-7. PubMed ID: 4403699
[No Abstract] [Full Text] [Related]
12. Inhibition of prolactin secretion and successful therapy of the Forbes-Albright syndrome with L-dopa.
Turkington RW
J Clin Endocrinol Metab; 1972 Feb; 34(2):306-11. PubMed ID: 5062099
[No Abstract] [Full Text] [Related]
13. Functional evaluation of prolactin secretion: a guide to therapy.
Friesen H; Guyda H; Hwang P; Tyson JE; Barbeau A
J Clin Invest; 1972 Mar; 51(3):706-9. PubMed ID: 4622109
[TBL] [Abstract][Full Text] [Related]
14. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Bell RD; Carruth A; Rosenberg RN; Boyar RM
J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Parkinson's syndrome with L-dopa].
Ljung O
Lakartidningen; 1972 Jun; 69(24):2940-4. PubMed ID: 5037135
[No Abstract] [Full Text] [Related]
16. Observations on patients with Parkinson's disease treated with L-dopa. I. Trial and evaluation of L-dopa therapy.
van Wieringen A; Wright J
S Afr Med J; 1972 Sep; 46(35):1262-6. PubMed ID: 4638222
[No Abstract] [Full Text] [Related]
17. [Clinical study of L-dopa in Parkinson's disease].
Franken L; Noel G; Lhoas JP; Meyers C; Noel P; Ectors M
Brux Med; 1972 Dec; 52(12):851-60. PubMed ID: 4575350
[No Abstract] [Full Text] [Related]
18. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
Figuerido JA; De la Herrán J
Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
[No Abstract] [Full Text] [Related]
19. [Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion].
Cavagnini F; Pontiroli AE; Raggi U; Peracchi M; Malinverni A
Folia Endocrinol; 1973 Dec; 26(6):483-9. PubMed ID: 4801258
[No Abstract] [Full Text] [Related]
20. Bensarazid with L-dopa in the treatment of parkinson's disease.
Van Wieringen A
S Afr Med J; 1974 Feb; 48(6):206-9. PubMed ID: 4814495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
